1. Introduction {#s0005}
===============

Type 2 diabetes (T2D) is currently one of the foremost health concerns, especially in developed countries. T2D is related to obesity and insulin resistance (IR), but the key mechanisms relating IR and T2D in obese subjects are yet to be determined. That said, inflammation, enhanced mitochondrial ROS production and the infiltration of leukocytes into the pancreas seem to be implicated [@bib1].

There is considerable evidence that a chronic, low-grade inflammatory response is ongoing in and actually precedes T2D and related syndromes [@bib2], [@bib3] and this inflammation may be due, in part, to the effects of hyperglycemia or other metabolic abnormalities on white blood cells [@bib4]. In this sense, it has been demonstrated that there is an activation of NFκB under IR conditions [@bib5], [@bib6]. In this chronic inflammatory state, inflammatory cells such as leukocytes are vulnerable to and markedly damaged by hyperglycemia. In fact, these actions can contribute to the undermined innate immune function and increased risk of infection among T2D patients [@bib7].

Oxidative stress and mitochondrial impairment have been implicated in the etiology of IR associated with T2D [@bib8], [@bib9]. The pathogenesis of mitochondrial dysfunction in obesity or any diabetes-related disease is multifactorial, and can also play an important role in pancreatic β cell failure in T2D [@bib10], [@bib11]. Furthermore, it has been demonstrated that mitochondria undergo biogenesis in response to high levels of glucose, but the increased biogenesis is insufficient to accommodate a high metabolic demand [@bib12]. In addition, obesity, which is related to T2D, is associated to increased levels of free fatty acids, inflammation, mitochondrial ROS and, therefore, oxidative stress [@bib13].

Leukocytes, and in particular polymorphonuclear leukocytes (PMNs), constitute a critical host defence against infections associated with T2D. Furthermore, PMNs may contribute to the oxidative stress and inflammation associated with T2D. In fact, the onset of atherosclerosis involves the recruitment of leukocytes to the endothelium, a process that begins when these cells roll over the endothelial cells and come to a halt, eventually adhering firmly. In this sense, a potential role of mitochondrial dynamics and function in the maintenance of endothelial cell function in T2D has been postulated [@bib14].

In the aforementioned context, therapies that decrease mitochondrial oxidative damage could help decrease the deleterious effects of T2D [@bib11]. Mitoquinone (MitoQ) is a mitochondria-targeted antioxidant derived from ubiquinone, and is targeted to mitochondria by covalent attachment to a lipophilic triphenylphosphonium (TPP) cation [@bib15], [@bib16], [@bib17]. Due to the large mitochondrial membrane potential, this cation is accumulated within the mitochondria inside cells. Mitochondria-targeted antioxidants are protective *in vivo* against oxidative damage in different pathologies, such as cancer, T2D, cardiovascular and neurodegenerative disorders [@bib18], [@bib19], [@bib20].

The aim of the current study was to evaluate the effect of MitoQ on oxidative stress parameters in leukocytes isolated from T2D patients, in particular the potential regulation of leukocyte-endothelial interactions and their effects on NFκB.

2. Materials and methods {#s0010}
========================

2.1. Subjects {#s0015}
-------------

98 T2D patients attending the Endocrinology and Nutrition Service of the University Hospital Doctor Peset (Valencia, Spain) and 71 controls adjusted by age and sex were enrolled in this study. T2D was diagnosed according to the American Diabetes Association\'s criteria. Diagnosis was confirmed when a patient fulfilled at least one of the following criteria: (1) levels of fasting serum glucose ≥126 mg/dl or random serum glucose ≥200 mg/dL on at least two occasions; (2) HbA1c ≥6.5%; or (3) antidiabetic medication. Subjects with any of the following conditions were excluded from the study: history of cardiovascular disease (including ischemic heart disease, stroke, peripheral vascular disease, and chronic disease related to cardiovascular risk); presence of morbid obesity; insulin treatment, autoimmune disease; and infectious, malignant, organic, haematological or inflammatory disease.

The study protocols were conducted according to the Helsinki Declaration and approved by the Ethics Committee of the University Hospital Doctor Peset. All participants underwent the process of informed consent required by these institutions.

Blood samples were collected in fasting conditions between 8 a.m. and 10 a.m. Subjects underwent an anthropometric and analytical assessment in which height (m), weight (kg), body mass index (BMI; kg/m^2^), waist circumference (cm), and systolic and diastolic blood pressure (SBP/DBP; mmHg) were measured.

2.2. Biochemical determinations {#s0020}
-------------------------------

Blood was obtained from the antecubital vein and centrifuged (1300*g*, 10 min, 4 °C), and biochemical determinations were performed as previously described [@bib21]. By means of an enzymatic method, total cholesterol, levels of glucose and triglycerides were determined in serum. Low density lipoprotein (LDL) content was calculated with Friedewald\'s formula, and high density lipoprotein (HDL) levels were obtained using a Beckman LX20 analyzer (Beckman Corp., CA, US). Insulin levels were determined by immunochemiluminescence, and insulin resistance was estimated using the homeostasis model assessment of insulin resistance (HOMA-IR=\[fasting insulin (μU/mL)×fasting glucose (mg/dl)\]/405). Percentage of HbA1c was determined with an automatic glycohemoglobin analyzer (Arkray Inc., Kyoto, Japan) and high-sensitive C-reactive protein (hs-CRP) levels were assessed by an immunonephelometric assay.

2.3. Cell isolation {#s0025}
-------------------

Leukocytes were isolated from heparinized blood samples that had been incubated with dextran (3%) for 45 min. Supernatant was collected, placed over Ficoll-Hypaque (GE Healthcare, Uppsala, Sweden) and spun at 650*g* for 25 min at room temperature. Erythrocytes remaining in the pellet were lysed with lysis buffer for 5 min at room temperature and centrifuged at 240*g*. The leukocyte pellet was then washed and resuspended in Hanks' balanced salt solution (HBSS; Sigma Aldrich, MO, US). Cells were counted with a Scepter 2.0 cell counter (Millipore Iberica, Madrid, Spain) and divided into different samples, one of which was incubated with 0.5 µM of MitoQ for 30 min, and the other with decyl-TPP in the same conditions.

2.4. Reactive oxygen species production {#s0030}
---------------------------------------

Mitochondrial ROS production was assessed using the fluorescent probe MitoSOX (5×10^−6^ mol/l, 30 min) by fluorometry using a fluorescence microscope (IX81; Olympus) coupled to the static cytometry software "ScanR" (Olympus). Nuclei were visualized with Hoechst 33342. Measures of fluorescence are referred to as % of control.

2.5. Western blot analysis {#s0035}
--------------------------

PMNs isolated from healthy or diabetic patients were resuspended at a density of 10^6^ cells/mL in 3 mL of complete RPMI (RPMI supplemented with 10% FBS). For each control or patient two samples were prepared: the control sample and the treated (0.5 µM MitoQ, 30 min) sample. The non-antioxidant decyl-TPP was also used as a control compound. In the meantime, two T25 flasks with confluent HUVEC were washed twice with PBS at 37 °C. Afterwards, PMN cells (control and MitoQ/TPP) were added to the HUVEC flask and incubated and shaken for 10 min (up to 130 rpm, mimicking the leukocyte-endothelium protocol) in a horizontal shaker at a fixed temperature of 37 °C. Cells were then pelleted and stored at −80 °C for subsequent determinations. Cell pellets were lysed on ice for 15 min with cell lysis buffer (20 mM HEPES pH 7.5, 400 mM NaCl, 20% Glycerol, 0.1 mM EDTA, 10 µm Na~2~MoO~4~, 0.5% NP-40, 1 mM dithiothreitol) and protein extraction was performed in the presence of a protease inhibitor mixture (10 mM NaF, 1 mM NaVO~3~, 10 mM PNP, 10 mM β-glycerolphosphate) [@bib22]. Protein concentrations were determined by a BCA protein assay (Thermo Scientific, IL, US) after 15 min centrifugation. Protein samples (25 μg) were resolved on 10% acrylamide gels and transferred onto nitrocellulose membrane. After blocking, membranes were incubated overnight with primary antibodies at 4 °C. The following primary antibodies were used: GPX-1 (Thermo Fisher), NFκB-p65 (Abcam), TNFα (Abcam) and Actin (Sigma). Blots were incubated with the secondary antibodies horseradish peroxidase (HRP) goat anti-mouse (Thermo Scientific) and HRP goat anti-rabbit (Millipore Iberica), and were developed for 2 min with ECL plus reagent (GE Healthcare) or Supersignal West Femto (Thermo Scientific). Visualization was by means of a Fusion FX5 acquisition system (Vilbert Lourmat, Marne La Valle´e, France). The signals were analyzed and quantified by densitometry using Bio1D software (Vilbert Lourmat) and all values were normalized to actin.

2.6. Leukocyte-endothelium interaction assay {#s0040}
--------------------------------------------

Adhesion assays under flow conditions were carried out using a parallel plate flow chamber *in vitro* model as previously described [@bib21]. Coverslips with confluent HUVEC monolayers were employed to perform the adhesion assays. These coverslips were inserted in the bottom plate of the flow chamber so that a 5×25 mm portion of the endothelial cells was exposed, and the flow chamber was mounted on an inverted microscope (Nikon Eclipse TE 2000-S) connected to a camera. Leukocyte suspensions were drawn across the HUVEC monolayer at a flow rate of 0.36 mL/min. Real time microscopic images of the flow-exposed monolayer were recorded for 5 min and examined. Leukocyte rolling velocity, rolling flux and adhesion were calculated as described elsewhere [@bib21]. TNFα (10 ng/mL, 4 h) was used as a positive control for HUVEC, and platelet activating factor (1 µM, 1 h) for leukocytes.

2.7. Data analysis {#s0045}
------------------

Data analysis was performed with SPSS 17.0. The values in Tables are mean±SD. Bar graphs show mean±SEM. Comparisons between 2 groups ([Table 1](#t0005){ref-type="table"}) were performed by a Student\'s *t*-test for normally distributed samples, and a Mann--Whitney *U* test for non-normally distributed samples. Chi-Square test was used to compare proportions among groups. Data were compared with a one-way analysis of variance (ANOVA) followed by a post hoc test. Analysis of covariance was employed to minimize the potential influence of BMI. Serum lipid and biochemical parameter changes were analyzed by means of a univariate general linear model using BMI as a covariate. Correlations were calculated using Spearman\'s correlation coefficient. Significant differences were considered when p\<0.05.

3. Results {#s0050}
==========

We evaluated 98 T2D patients and 71 control subjects ([Table 1](#t0005){ref-type="table"}). Diabetic patients exhibited higher weight, BMI, waist circumference, SBP, DBP, fasting glucose, insulin, HOMA-IR and HbA1c (*p*\<0.001) than controls. When data were adjusted by BMI, statistical differences remained unchanged. The lipid profile of diabetic subjects was characterized by higher triglyceride and lower HDL-c levels with respect to controls (*p*\<0.001). However, due to the lipid-lowering treatment received by most of the T2D patients (65% of patients were taking statins and 6% ezetimibe), levels of total cholesterol and LDL-c were lower than in controls (*p*\<0.001). Inflammation, measured as hs-CRP levels, was also more pronounced in diabetic patients *vs* controls (*p*\<0.001). Statistical differences remained when analyses were adjusted by BMI (*p*\<0.01).

3.1. Mitochondrial ROS and glutathione peroxidase levels {#s0055}
--------------------------------------------------------

Leukocytes from diabetic patients displayed enhanced levels of MitoSOX oxidation, which is consistent with an increase in mitochondrial ROS production ([Fig. 1](#f0005){ref-type="fig"}A, *p*\<0.01). However, the mitochondrial targeted antioxidant MitoQ decreased MitoSOX oxidation in diabetic leukocytes (*p*\<0.05) to values similar to those in controls. MitoQ did not alter MitoSOX oxidation in controls ([Fig. 1](#f0005){ref-type="fig"}A).

When glutathione peroxidase 1 (GPX-1) was evaluated by western blot, differences were not observed between diabetic and control subjects ([Fig. 1](#f0005){ref-type="fig"}B). The presence of MitoQ increased GPX1 levels in diabetic cell pellets (*p*\<0.05) with respect to control and diabetic groups without MitoQ.

None of these oxidative stress parameters were affected by decyl-TPP treatment ([Fig. 1](#f0005){ref-type="fig"}A--B).

3.2. Leukocyte-endothelium interactions {#s0060}
---------------------------------------

When leukocyte-endothelium interactions were assessed in controls and T2D patients, a decrease in leukocyte rolling velocity ([Fig. 2](#f0010){ref-type="fig"}A, *p*\<0.001) and an increase in leukocyte rolling flux ([Fig. 2](#f0010){ref-type="fig"}B, *p*\<0.001) and adhesion ([Fig. 2](#f0010){ref-type="fig"}C, *p*\<0.01) were observed in T2D patients. Those effects were reversed in the presence of MitoQ, which increased leukocyte rolling velocity ([Fig. 2](#f0010){ref-type="fig"}A, *p*\<0.05) and reduced leukocyte rolling flux ([Fig. 2](#f0010){ref-type="fig"}B, *p*\<0.05) and adhesion ([Fig. 2](#f0010){ref-type="fig"}C, *p*\<0.01) in T2D patients. MitoQ had no effects in controls and decyl-TPP had no effect on leukocyte-endothelium interactions.

3.3. Levels of NFκB-p65 and TNFα {#s0065}
--------------------------------

Diabetic patients showed an increase in NFκB-p65 levels ([Fig. 3](#f0015){ref-type="fig"}A, *p*\<0.05). MitoQ decreased the levels of NFκB-p65 in those cells ([Fig. 3](#f0015){ref-type="fig"}A, *p*\<0.05), showing an anti-inflammatory effect, and did not modify NFκB-p65 levels in the control condition. In addition, NFκB-p65 levels correlated negatively with GPX1 levels (*p\<*0.05; r=−0.566) and positively with glucose levels (*p*\<0.05; r=0.564) and PMN rolling flux (*p*\<0.05; r=0.576).

In relation to TNFα levels, there was an increase in diabetic patients ([Fig. 3](#f0015){ref-type="fig"}B, *p*\<0.05) to a similar extent as that observed with NFκB-p65 levels, and MitoQ again exerted an anti-inflammatory effect by reducing TNFα levels ([Fig. 3](#f0015){ref-type="fig"}B, *p*\<0.05). MitoQ did not have any effect on control pellets. Furthermore, TNFα levels correlate positively with PMN rolling flux (p\<0.05; r=0.580) and NFκB-p65 (p\<0.001; r=0.860).

Decyl-TPP treatment did not affect NFκB-p65 or TNFα levels.

4. Discussion {#s0070}
=============

In the present study we report an increase in fasting levels of glucose, insulin, HOMA-IR, triglycerides, HbA1c and hs-CRP in T2D patients. Given that BMI was also higher in this group, we adjusted the data for this parameter, obtaining the same results.

Vascular complications and oxidative stress are features of T2D. Furthermore, oxidative stress is a key event in the immunobiology of inflammatory responses. In previous studies we have shown that oxidative stress and mitochondrial dysfunction are present in the leukocytes of T2D patients and are enhanced in patients with vascular complications [@bib21], [@bib23]. In the present study we have determined that increased mitochondrial ROS production occurs in leukocytes of T2D patients, suggesting that leukocyte oxidative stress and mitochondrial function are altered during long-term exposure to glucose.

Several studies have demonstrated that mitochondrial antioxidant enzymes can protect against oxidant-induced damage under hyperglicemic conditions [@bib24], [@bib25]. Furthermore, protecting mitochondria seems to play an important role in arteriogenesis and angiogenesis under oxidative stress conditions [@bib26]. For these reasons, we believe that mitochondria-targeted antioxidants can modulate oxidative stress and may have beneficial effects in T2D. We have used MitoQ because this compound is biocompatible and can be administered safely *in vivo* with no reported toxic effects. In fact, MitoQ can prevent ischemia/reperfusion-induced cardiac dysfunction [@bib27] and also protects against endothelial dysfunction in *in vivo* and *in vitro* models [@bib28], [@bib29]. MitoQ has also demonstrated beneficial effects by preventing diabetic nephropathy in Ins2^+/Akita\ J^ mice [@bib18], or by modulating muscle lipid profile and improving mitochondrial respiration in obesogenic diet-fed rats [@bib30]. However, it has been also demonstrated that TPP^+^ compounds such as MitoQ can disrupt mitochondrial function at concentrations frequently observed in cell culture and that this behaviour is dependent on the linker group and independent of antioxidant properties [@bib31].

ROS may have important roles in hyperglycemia-mediated endothelial dysfunction and microvascular complications associated to IR [@bib32], [@bib33]. Indeed, it has been demonstrated that T2D patients have an increased risk of developing cardiovascular events, which may be related to oxidative stress [@bib21]. In relation to this, the results of the present study show that treatment with MitoQ reduces levels of ROS and increases those of GPX1, thus exhibiting an antioxidant effect. Indeed, it has been previously demonstrated that MitoQ can reduce ROS and modulate GPX1 under oxidative stress conditions such as propionic acidemia [@bib34].

Hypertension and atherosclerosis are inflammatory states characterized by leukocyte recruitment to arterial walls [@bib35]. We have used an *in vitro* system to study this process, in which human leukocytes flow over a monolayer of human endothelial cells with a shear rate equivalent to that observed *in vivo* [@bib36]. This mimics the process of rolling and adhesion that precedes inflammation *in vivo*, and which is essential to maintain vascular homeostasis and integrity. If these interactions are enhanced, endothelial dysfunction and vascular damage associated with many CVD can take place. In previous studies, we have demonstrated that T2D patients display features of chronic inflammation and enhanced leukocyte-endothelium interactions, and that these disturbances can be aggravated in the presence of vascular complications [@bib21], [@bib22], [@bib23]. Our findings show that the inflammatory state is enhanced in T2D patients. In fact, we have witnessed an increase in PMN rolling flux and adhesion and a decrease in PMN rolling velocity by which leukocyte-endothelium interactions were induced. Interestingly, we have seen that treatment with MitoQ increases PMN rolling velocity and decreases PMN rolling flux and adhesion in the leukocytes of T2D patients, suggesting a protective cardiovascular role. Indeed, MitoQ has previously been reported to decrease ischemia-reperfusion injury in a murine syngeneic heart transplant model [@bib37] and to decrease features of metabolic syndrome in an ATM+/-/ApoE-/- mice model [@bib38].

NFκB is a common inflammatory factor and plays an important role in the regulation of cytokines in diabetic nephropathy [@bib39]. Furthermore, NFκB activity is significantly increased in T2D patients with nephropathy compared to those without renal impairment [@bib5], [@bib40]. In line with these studies, we report that the expression of p65-NFκB is increased in T2D patients, thus highlighting the importance of this transcription factor. In addition, NFκB levels correlate positively with glucose levels, which confirms that hyperglycemia is closely associated with inflammation. In this sense, a previous study showed that inhibition of the IKKβ/NFκB pathway improves glucose tolerance in obese mice, pointing to a central role of this signaling pathway in the development of T2D [@bib41]. We also found a negative association between p65-NFκB and GPX1, which was reported in a previous study in which lack of GPX1 promoted upregulation of p65-NFκB in mouse aortas [@bib42]. Moreover, we have observed an increase in the proinflammatory cytokine TNFα; interestingly, treatment with MitoQ decreased the levels of NFκB and, in consequence, those of TNFα. In relation with this, it has been demonstrated that mitochondria-targeted antioxidants such as MitoTempol and MitoQ can protect pancreatic β-cells against oxidative stress by decreasing NFκB activity, promoting their survival, and increasing insulin secretion in cell models of the glucotoxicity and glucolipotoxicity associated with T2D [@bib43]. Interestingly, we have seen that both NFκB and TNFα levels correlate positively with leukocyte rolling flux, highlighting the role of these proinflammatory markers in the atherosclerotic process.

Our study reveals a potential protective role of mitochondrial targeted antioxidants in the vasculature. However, a larger cohort of patients would have provided more conclusive observations, especially with respect to the correlation studies. In addition, a control group with a similar BMI to that of our T2D patients would have strengthened our comparisons.

Overall, our findings provide a better understanding of the pathophysiological mechanisms occurring in leukocytes/endothelium of T2D patients. They suggest that increased inflammation and oxidative stress, together with NFκB activation and increased proinflammatory cytokine TNFα, contribute to the enhanced interaction between these cells, which augments the risk of CVD. Importantly, treatment with MitoQ modulates these actions, thus preventing oxidative stress and chronic inflammation, which suggests that this compound has potential beneficial effects for preventing cardiovascular diseases in T2D.
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![(A) Levels of MitoSox oxidation in controls and T2D patients in presence and absence of MitoQ or decyl-TPP (30 min, 0.5 µM) and representative fluorescence microscopy images (B) Levels of GPX-1 (25 kDa) measured by Western blot in controls and T2D patients in presence and absence of MitoQ or decyl-TPP (30 min, 0.5 µM). \* p\<0.05 and \*\*p\<0.01vs control; ^a^p\<0.05 *vs* T2D patients.](gr1){#f0005}

![Leukocyte/endothelium interactions in T2D patients and control subjects in presence and absence of MitoQ or decyl-TPP (30 min, 0.5 µM). (A) PMN rolling velocity (μmsecond^-1^), (B) rolling flux (PMN per minute) and (C) PMN adhesion (PMN per square millimetre). \*\*p\<0.01 and \*\*\*p\<0.001 *vs* control. ^a^p\<0.05 and ^b^p\<0.01 *vs* T2D patients.](gr2){#f0010}

![Evaluation of protein expression by Western blot of p65-NFκB (55 kDa) (A) and TNFα (23 kDa) (B) in T2D patients and control subjects in presence and absence of MitoQ or decyl-TPP (30 min, 0.5 µM). \*p\<0.05 *vs* control. ^a^p\<0.05 *vs* T2D patients.](gr3){#f0015}

###### 

Baseline characteristics of the study population.

Table 1

                              **Control**         **T2D**               **p Value**   **BMI-adjusted p Value**
  --------------------------- ------------------- --------------------- ------------- --------------------------
  N                           71                  98                    --            
  Male %                      45.1                51.7                  0.452         
  Age (years)                 57.5±8.2            59.1±8.3              0.263         
  Weight (kg)                 70.6±12.0           82.2±13.7             \<0.001       
  BMI (kg/m^2^)               25.8±4.0            30.7±4.4              \<0.001       
  Waist (cm)                  88.4±14.3           105.5±10.4            \<0.001       
  SBP (mmHg)                  129±21              143±21                \<0.001       \<0.01
  DBP (mmHg)                  74±10               83±15                 \<0.001       \<0.01
  Glucose (mg/dl)             91.6±12.6           146.8±49.4            \<0.001       \<0.001
  Insulin (μUI/mL)            8.43±4.48           15.70±10.91           \<0.001       \<0.001
  HOMA-IR                     1.99±1.18           5.50±4.19             \<0.001       \<0.001
  HbA1c (%)                   5.27±0.28           6.97±1.11             \<0.001       \<0.001
  Total cholesterol (mg/dl)   193.7±39.3          168.8±37.5            \<0.001       \<0.001
  HDL-c (mg/dl)               54.4±11.3           45.1±10.7             \<0.001       \<0.001
  LDL-c (mg/dl)               121.1±31.7          96.2±32.8             \<0.001       \<0.001
  Triglycerides (mg/dl)       74.0 (59.5; 97.0)   114.0 (87.0; 157.8)   \<0.001       \<0.001
  hs-CRP (mg/l)               0.94 (0.46; 2.53)   3.46 (1.37; 5.72)     \<0.001       \<0.001

Data are expressed as mean±SD for parametric data or as median (25th and 75th percentiles) for non-parametric data. Means were compared by a Student\'s *t*-test for normally distributed samples and a Mann--Whitney *U* test for non-normally distributed samples. Adjustments by BMI were performed by means of a univariate general linear model. A Chi-Square test was used to compare proportions among groups. HOMA-IR=fasting insulin (μU/ml) x fasting glucose (mg/dl)/405.
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